Welcome to our dedicated page for Silexion Therapeutics SEC filings (Ticker: SLXNW), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Silexion Therapeutics's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Silexion Therapeutics's regulatory disclosures and financial reporting.
Silexion Therapeutics Corp is asking shareholders at a March 16, 2026 extraordinary general meeting to approve two key changes. The first would increase authorized share capital from 9,000,000 to 59,000,000 ordinary shares, mainly to support financing, business development and compliance with Nasdaq’s $2.5 million shareholders’ equity requirement. The second would amend the 2024 Equity Incentive Plan so the annual “evergreen” refresh can raise the total equity incentive pool up to 10% of issued and outstanding ordinary shares on a fully diluted basis. As of February 23, 2026, Silexion had 3,330,785 ordinary shares outstanding. The board unanimously recommends voting in favor of both proposals.
Silexion Therapeutics Corp is asking shareholders at a March 16, 2026 extraordinary general meeting to approve two key changes. The first would increase authorized share capital from 9,000,000 to 59,000,000 ordinary shares, mainly to support financing, business development and compliance with Nasdaq’s $2.5 million shareholders’ equity requirement. The second would amend the 2024 Equity Incentive Plan so the annual “evergreen” refresh can raise the total equity incentive pool up to 10% of issued and outstanding ordinary shares on a fully diluted basis. As of February 23, 2026, Silexion had 3,330,785 ordinary shares outstanding. The board unanimously recommends voting in favor of both proposals.
Silexion Therapeutics Corp received an amended Schedule 13G reporting that Mitchell P. Kopin, Daniel B. Asher and Intracoastal Capital LLC together beneficially own 325,000 ordinary shares, or about 9.4% of the company, as of December 31, 2025.
The reported position consists entirely of warrants held by Intracoastal Capital LLC, which are exercisable into 325,000 ordinary shares through two separate warrants of 162,500 shares each. All voting and dispositive power over these shares is shared among the reporting persons, with no sole voting or dispositive authority.
An additional 32,100 shares underlying a third warrant are excluded because that warrant has a 4.99% beneficial ownership blocker, which limits exercises that would push the group’s ownership above that threshold.
Silexion Therapeutics Corp received an amended Schedule 13G reporting that Mitchell P. Kopin, Daniel B. Asher and Intracoastal Capital LLC together beneficially own 325,000 ordinary shares, or about 9.4% of the company, as of December 31, 2025.
The reported position consists entirely of warrants held by Intracoastal Capital LLC, which are exercisable into 325,000 ordinary shares through two separate warrants of 162,500 shares each. All voting and dispositive power over these shares is shared among the reporting persons, with no sole voting or dispositive authority.
An additional 32,100 shares underlying a third warrant are excluded because that warrant has a 4.99% beneficial ownership blocker, which limits exercises that would push the group’s ownership above that threshold.
Silexion Therapeutics Corp furnished an investor presentation in connection with a non-deal roadshow. The company prepared a corporate presentation dated February 2026 for use in meetings with investors, and attached it as Exhibit 99.1. This material is provided under Regulation FD as a furnished, not filed, communication under securities laws.
Silexion Therapeutics Corp furnished an investor presentation in connection with a non-deal roadshow. The company prepared a corporate presentation dated February 2026 for use in meetings with investors, and attached it as Exhibit 99.1. This material is provided under Regulation FD as a furnished, not filed, communication under securities laws.
Silexion Therapeutics Corp Schedule 13D/A reports that Moringa-related parties disclosed ownership totaling approximately 14.6% of the company's ordinary shares. The filing states Silexion issued 450,000 ordinary shares to Moringa Sponsor, LP on September 15, 2025, in conversion of $1.8 million of an outstanding promissory note, but the Reporting Persons expressly dispute the validity of that issuance and do not concede beneficial ownership of those shares. The cover-page totals combine 6,970 issued ordinary shares, 372 ordinary shares underlying warrants and the 450,000 shares the Reporting Persons contest. The Reporting Persons also reported a pro rata distribution on August 7, 2025 of certain shares and warrants to limited partners.
Silexion Therapeutics Corp Schedule 13D/A reports that Moringa-related parties disclosed ownership totaling approximately 14.6% of the company's ordinary shares. The filing states Silexion issued 450,000 ordinary shares to Moringa Sponsor, LP on September 15, 2025, in conversion of $1.8 million of an outstanding promissory note, but the Reporting Persons expressly dispute the validity of that issuance and do not concede beneficial ownership of those shares. The cover-page totals combine 6,970 issued ordinary shares, 372 ordinary shares underlying warrants and the 450,000 shares the Reporting Persons contest. The Reporting Persons also reported a pro rata distribution on August 7, 2025 of certain shares and warrants to limited partners.
Silexion Therapeutics Corp Schedule 13D/A reports that Moringa-related parties disclosed ownership totaling approximately 14.6% of the company's ordinary shares. The filing states Silexion issued 450,000 ordinary shares to Moringa Sponsor, LP on September 15, 2025, in conversion of $1.8 million of an outstanding promissory note, but the Reporting Persons expressly dispute the validity of that issuance and do not concede beneficial ownership of those shares. The cover-page totals combine 6,970 issued ordinary shares, 372 ordinary shares underlying warrants and the 450,000 shares the Reporting Persons contest. The Reporting Persons also reported a pro rata distribution on August 7, 2025 of certain shares and warrants to limited partners.
The reporting persons—Lind Global Fund III LP, Lind Global Partners III LLC and Jeff Easton—filed a Schedule 13G reporting beneficial ownership of 224,050 ordinary shares of Silexion Therapeutics Corp (CUSIP G1281K122), representing 9.9% of the class. The disclosed position consists of 106,250 ordinary shares and warrants (106,250 Series A-1 and 106,250 Series A-2) subject to conversion limits that cap aggregate beneficial ownership at 224,050 shares to prevent ownership above 9.99%. Lind Global Partners III LLC is the general partner of the fund and Jeff Easton is the managing member; each may be deemed to have sole voting and dispositive power over the reported shares. The filers certify the holdings were not acquired to change or influence control of the issuer.
Silexion Therapeutics Corp disclosed that three reporting persons—Intracoastal Capital, LLC, Mitchell P. Kopin and Daniel B. Asher—may each be deemed to beneficially own 244,771 ordinary shares, representing 9.99% of the class as of close of business on September 17, 2025. The filing explains these shares arise primarily from warrants issued under a Securities Purchase Agreement and notes multiple warrants include blocker provisions that limit exercise to prevent ownership above 9.99% (and 4.99% for one warrant). Voting and dispositive power over the 244,771 shares is reported as shared rather than sole.
Orca Capital AG reported beneficial ownership of 109,432 ordinary shares of Silexion Therapeutics Corp, representing 4.9% of the outstanding class based on 2,123,892 shares outstanding after the issuer's registered offering. The filing clarifies that the reporting person also holds warrants for 153,068 ordinary shares but cannot exercise them to the extent doing so would increase beneficial ownership above 4.99% (the "4.99% Blocker"). Orca states the securities were not acquired to change or influence control of the issuer and reports sole voting and dispositive power over the reported shares.
Orca Capital AG reported beneficial ownership of 109,432 ordinary shares of Silexion Therapeutics Corp, representing 4.9% of the outstanding class based on 2,123,892 shares outstanding after the issuer's registered offering. The filing clarifies that the reporting person also holds warrants for 153,068 ordinary shares but cannot exercise them to the extent doing so would increase beneficial ownership above 4.99% (the "4.99% Blocker"). Orca states the securities were not acquired to change or influence control of the issuer and reports sole voting and dispositive power over the reported shares.
Orca Capital AG reported beneficial ownership of 109,432 ordinary shares of Silexion Therapeutics Corp, representing 4.9% of the outstanding class based on 2,123,892 shares outstanding after the issuer's registered offering. The filing clarifies that the reporting person also holds warrants for 153,068 ordinary shares but cannot exercise them to the extent doing so would increase beneficial ownership above 4.99% (the "4.99% Blocker"). Orca states the securities were not acquired to change or influence control of the issuer and reports sole voting and dispositive power over the reported shares.